A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

This was the stock's third consecutive day of gains.